Published in Arch Pediatr on October 02, 2011
Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev (2015) 0.78
A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother (2000) 3.47
Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis (1988) 3.35
Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother (1991) 3.08
Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly. Antimicrob Agents Chemother (2001) 3.03
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1995) 2.56
Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother (2002) 2.31
A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother (2000) 2.22
Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother (2003) 2.16
CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother (2002) 2.09
Prospective survey of colonization and infection caused by expanded-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae in an intensive care unit. J Clin Microbiol (1989) 2.07
Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother (1999) 1.98
A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother (2000) 1.86
Comparative study of five plasmid-mediated ceftazidimases isolated in Klebsiella pneumoniae. J Antimicrob Chemother (1989) 1.74
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother (1994) 1.64
Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains. J Antimicrob Chemother (1996) 1.64
Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors. J Antimicrob Chemother (1994) 1.57
Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate. Antimicrob Agents Chemother (1991) 1.54
Translocation of antibiotic resistance determinants including an extended-spectrum beta-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (1991) 1.52
First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother (1995) 1.40
Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med (2000) 1.38
TEM derivative-producing Enterobacter aerogenes strains: dissemination of a prevalent clone. Antimicrob Agents Chemother (2002) 1.32
Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother (2004) 1.26
Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases. Clin Microbiol Infect (2006) 1.24
TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob Agents Chemother (2005) 1.21
Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother (2000) 1.10
New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates. Antimicrob Agents Chemother (2001) 1.03
Extended-spectrum beta-lactamase TEM-24 in an Aeromonas clinical strain: acquisition from the prevalent Enterobacter aerogenes clone in France. Antimicrob Agents Chemother (2003) 1.01
Operation Everest III (Comex '97): modifications of cardiac function secondary to altitude-induced hypoxia. An echocardiographic and Doppler study. Am J Respir Crit Care Med (2000) 1.01
Neurologic decompression illness: a gravity score. Undersea Hyperb Med (1996) 0.99
Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9. Antimicrob Agents Chemother (2003) 0.96
Novel plasmid-mediated ceftazidimase from Klebsiella pneumoniae isolates. J Antimicrob Chemother (1988) 0.91
Identification of two novel TEM-derivative ceftazidimases, CAZ-6 and CAZ-7, from Klebsiella pneumoniae isolates. J Antimicrob Chemother (1989) 0.90
[Prognosis in iatrogenic gas embolism]. Minerva Med (1995) 0.86
Haemoconcentration in neurological decompression illness. Int J Sports Med (1996) 0.84
Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1. Infection (1989) 0.84
A new simple method to perform pressure-volume curves obtained under quasi-static conditions during mechanical ventilation. Intensive Care Med (1999) 0.84
Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother (1989) 0.84
Factors associated with antimicrobial resistance among clinical isolates of Klebsiella pneumoniae: 1-year survey in a French university hospital. Eur J Clin Microbiol Infect Dis (2004) 0.84
Diagnosis of nosocomial pneumonia in mechanically ventilated patients: repeatability of the bronchoalveolar lavage. Am J Respir Crit Care Med (1998) 0.81
Unexpected enzyme TEM-126: role of mutation Asp179Glu. Antimicrob Agents Chemother (2005) 0.80
Inhibitor-resistant TEM-33 beta-lactamase in a Shigella sonnei isolate. Antimicrob Agents Chemother (2001) 0.80
[Detection of beta-lactamases resistant to inhibitors (IRT) by the disk diffusion method]. Pathol Biol (Paris) (1995) 0.77
Venous gas embolism: detection with pulsed Doppler guided by two-dimensional echocardiography. Acta Anaesthesiol Scand (1999) 0.76
[Kangaroo mother care vs nidcap: a problem of semantics]. Arch Pediatr (2005) 0.75
[Development of widely available reference frames of pediatrics in maternity in the Languedoc-Roussillon region]. Arch Pediatr (2007) 0.75
[Pregnancies occurring after a perinatal death. Preparation of a psychological risk index]. J Gynecol Obstet Biol Reprod (Paris) (1988) 0.75
[In vitro antibacterial activity of piperacillin-tazobactam combination on hospital isolates and regression curve]. Pathol Biol (Paris) (1991) 0.75
[In vitro antibacterial activity of RU 51746 (sodium salt of cefpodoxime). Results of a multicenter study]. Pathol Biol (Paris) (1990) 0.75
[Medical interruptions of pregnancies before 14 weeks of gestation: is it always necessary to go faster?]. J Gynecol Obstet Biol Reprod (Paris) (2011) 0.75
Circulating bioactive inhibin levels during human pregnancy. J Clin Endocrinol Metab (1991) 0.75
[Techniques, results and indications of embryonic reductions in multiple pregnancies. Review of the literature]. J Gynecol Obstet Biol Reprod (Paris) (1991) 0.75
Effect of epidermal growth factor on inhibin secretion in human placental cell culture. Endocrinology (1992) 0.75
[The physician and the disclosure of handicap in the newborn]. Arch Fr Pediatr (1989) 0.75
[Weaning from mechanical ventilation facilitated by colostomy in a patient with colonic dilatation]. Presse Med (1994) 0.75
[Early prenatal interview: implementation of a sheet link "carried" by patient. The Aurore perinatal network experience]. J Gynecol Obstet Biol Reprod (Paris) (2008) 0.75
Ascent rate and circulating venous bubbles in recreational diving. Int J Sports Med (2000) 0.75
[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB++STREP strip]. Pathol Biol (Paris) (1996) 0.75
[Haemophilus parainfluenzae meningitis in an 8-year-old boy]. Presse Med (1993) 0.75
[Piperacillin-amikacin combinations: killing curves]. Pathol Biol (Paris) (1990) 0.75